Role of the long-acting somastatin analogue Sandostatin Lar in the treatment of acromegaly
- 作者: Molitvoslovova N1, Alekseeva T1, Antsiferov M1, Molitvoslovova N.N.1, Alekseeva T.M.1, Antsiferov M.B.1
-
隶属关系:
- 期: 编号 11 (2010)
- 页面: 72-76
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278480
- ID: 278480
如何引用文章
全文:
详细
作者简介
N Molitvoslovova
T Alekseeva
M Antsiferov
Natal'ya Molitvoslovova
Tat'yana Alekseeva
Mikhail Antsiferov
参考
- Acromegaly - pathology, diagnosis and treatment. Taylor and Francis group, LLC. USA 2005:151.
- Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004;89(4):1613-17.
- Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2(1):29-41.
- Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89(2):667-74.
- Rajasoorya C, Holdaway MP, Scott DJ. et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41(1):95-102.
- Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004;25(1):102-52.
- Medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. AACE. Endocrine practice 2004;10(3):213-25.
- Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153:737-40.
- Melmed S, Casanueva FF, Cavagnini F, et al. Consensus. Guidelines for acromegly management. J Clin Endocrinol Metab 2002;87(9):4054-58.
- Burt MG, Ho KKY. Newer options in the management of acromegaly. Intern Med J 2006;36:437-44.
- Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85(2):526-29.
- Kreuter J, Vance ML, Lopes MB, et al. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001;86:4072-77.
- Fahlbusch R, Buchfelder M, Kreutzer J, et al. Surgical management of acromegaly. Handbook of acromegaly/ed.J.Wass. Published by Bioscientifica, Bristol, UK 2001:41-7.
- Barkan A. Radiotherapy in acromegaly: the argument against. Clin Endocrinol 2003;58:132-35.
- Jane JA, Vance ML, Woodburn CJ, et al. Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach. Neurosurgis 2003;14:1-5.
- Davies PH, Stewart SE, Lancranjan I, et al. Long-term therapy with long acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol 1998;48:311-16.
- Lancranjan I, Atkinson AB, & the Sandostatin LAR Group. Results of a European Multicentre study with sandostatin LAR in acromegaly patients. Pituitary 1999;1:105-14.
- Colao A, Cuocolo A, Marzullo P, et al. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999;84(1):17-23.
- Ip MSM, Tan KCB, Peh WCG, et al. Effect of sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol 2001;55:477-83.
- Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86(6):2779-86.
- Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87:4554-63.
- Bevan J. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90(3):1856-63.
- Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90(8):4465-73.
- Colao A, Pivonello RR, Rosato F, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol 2006;64:342-51.
- Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long - term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91(4):1397-403.
- Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83(8):2730-34.